PT-141 (Bremelanotide): Published Research

Introduction

Bremelanotide (PT-141) has been the subject of a substantial body of peer-reviewed research spanning more than two decades, from early preclinical characterization through phase 1 and phase 2 dose-finding studies to the phase 3 RECONNECT program that supported its 2019 FDA approval as Vyleesi. This article summarizes the methodology and reported findings of the principal published studies, with attention to research design, measured outcomes, and the progression of knowledge across the development timeline. All findings are attributed to their source publications and are not SpartaLabs claims.

Methodology Types in the Published Literature

The published research base on bremelanotide spans several distinct methodological categories: preclinical rodent and primate studies characterizing receptor binding and neuronal activation; phase 1 pharmacokinetic studies in healthy volunteers examining both intranasal and subcutaneous formulations; phase 2 dose-finding trials in premenopausal women with diagnosed conditions, using validated psychometric scales as endpoints; the pivotal RECONNECT phase 3 program of two parallel randomized controlled trials; a 52-week open-label safety extension; and functional neuroimaging (fMRI) research examining neural substrates of melanocortin receptor agonism.

Summary of Published Studies

Early Preclinical and Phase 1 Characterization (2003–2004)

Diamond and colleagues (2003) reported comprehensive characterization of PT-141 as a melanocortin receptor agonist in the Annals of the New York Academy of Sciences [1]. The authors described preclinical findings in rats and non-human primates and summarized early clinical data in men, reporting dose-dependent changes following peptide administration. The authors concluded that the compound held scientific interest as a centrally-acting melanocortin agonist with a mechanistically distinct profile from phosphodiesterase type 5 (PDE5) inhibitors.

Diamond and colleagues (2004) subsequently published data from a double-blind, placebo-controlled phase 1 study evaluating the intranasal formulation in healthy males and patients with mild-to-moderate erectile dysfunction [2]. The study documented pharmacokinetic parameters alongside pharmacodynamic observations. Blood pressure monitoring data were collected as part of the safety characterization, and the authors characterized cardiovascular parameters as findings that informed subsequent formulation choices in the development program.

Cardiovascular Safety Characterization (2008–2017)

Safarinejad and Hosseini (2008) reported a randomized, double-blind, placebo-controlled study of intranasal bremelanotide in men with erectile dysfunction who had not responded to sildenafil [3]. Among 342 participants randomized to receive bremelanotide or placebo, the authors reported statistically significant differences in erectile function measures in favor of bremelanotide. The blood pressure observations from this intranasal formulation study, along with the nausea profile, informed the subsequent reformulation strategy for subcutaneous delivery — a transition that characterized the next phase of the clinical program.

Halpern and colleagues (2017) published an ambulatory blood pressure monitoring study characterizing the cardiovascular profile of the subcutaneous formulation of bremelanotide [4]. The authors reported that subcutaneous bremelanotide was associated with mean increases in systolic and diastolic blood pressure of approximately 4 mmHg persisting for approximately four hours following each administration. The authors characterized this profile as consistent with the compound's known pharmacology and noted that the subcutaneous route produced a substantially more predictable and attenuated cardiovascular signal than the intranasal formulation characterized in earlier studies [4].

Phase 2b Dose-Finding Trial (2017)

Portman and colleagues (2017) published results of a randomized, placebo-controlled phase 2b dose-finding trial of subcutaneous bremelanotide in 397 premenopausal women with a diagnosis of hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), or both [5]. The study evaluated three active doses over 12 weeks. The authors reported that the 1.75 mg subcutaneous dose was associated with statistically significant differences from placebo across multiple pre-specified psychometric endpoints, including the Female Sexual Function Index-desire domain and the Female Sexual Distress Scale. This dose-finding outcome provided the basis for the dose selection in the subsequent phase 3 program.

RECONNECT Phase 3 Trials (2019)

Simon and colleagues (2019) published the primary efficacy and safety results from the two parallel RECONNECT phase 3 trials in Obstetrics & Gynecology [6]. The two trials enrolled 1,267 premenopausal women with acquired, generalized HSDD, randomizing participants 1:1 to subcutaneous bremelanotide 1.75 mg or matching placebo on an as-needed basis over 24 weeks. The co-primary efficacy endpoints were change from baseline in the Female Sexual Function Index-desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 score.

The authors reported that bremelanotide was associated with statistically significant differences from baseline relative to placebo on both co-primary endpoints across both trials. The treatment difference was characterized by the investigators as clinically meaningful. The adverse event profile was consistent with the phase 2b characterization, with nausea reported as the most common adverse event; the majority of events were mild to moderate in severity. These data supported the NDA submission and the 2019 FDA approval of Vyleesi.

Long-Term Open-Label Extension (2019)

Kingsberg and colleagues (2019) reported 52-week data from the open-label extension of the RECONNECT program, in which participants who had completed the randomized phase could continue receiving bremelanotide [7]. The study enrolled 684 participants. The authors reported that no new safety signals were identified over the extended observation period, and that the adverse event profile in the open-label extension was consistent with that observed in the randomized phase. The extension study provided the longest published safety dataset available for bremelanotide at the time of regulatory approval.

Neuroimaging Research (2022)

Browning and colleagues (2022) reported results of a randomized, double-blind, placebo-controlled crossover study using functional magnetic resonance imaging (fMRI) to characterize the neural effects of MC4R agonism in 31 premenopausal women [8]. Participants received a single dose of a selective MC4R agonist or placebo on separate sessions. During fMRI scanning, participants viewed sexual and neutral visual stimuli. The authors reported that MC4R agonism was associated with differential brain activity patterns in the cerebellum, supplementary motor area, and secondary somatosensory cortex, as well as enhanced amygdala-insula functional connectivity. The authors interpreted these findings as consistent with altered self-referential processing and changes in the salience of erotic stimuli — a mechanistic characterization that complements the clinical trial endpoint data [8].

Pooled Safety Analysis Across Clinical Development (2022)

Clayton and colleagues (2022) published a pooled safety analysis of bremelanotide data across the clinical development program [9]. The analysis consolidated adverse event data from multiple studies and characterized the overall safety profile. The authors reported that transient nausea, flushing, and headache were the predominant adverse events. Across the development program, the transition from intranasal to subcutaneous delivery was associated with a more predictable cardiovascular signal, and no unexpected safety findings emerged in the pooled dataset [9].

Active Research Frontiers

The neural circuit mechanisms by which MC4R agonism in the hypothalamus and limbic system produces the clinical effects measured in the RECONNECT trials represent an active area of ongoing investigation. The neuroimaging data reported by Browning and colleagues (2022) complement the clinical trial evidence and open avenues for mechanistic characterization at the circuit level.

The relative contributions of MC3R and MC4R agonism to bremelanotide's biological effects remain scientifically open, as do the mechanistic bases for the pharmacological observations in early-phase male-population studies — both documented in the peer-reviewed literature and present in the active scientific record of melanocortin receptor pharmacology [1, 2]. The broader melanocortin receptor field continues to yield findings across multiple therapeutic areas, reflected in the 2020 FDA approval of the MC4R agonist setmelanotide for genetic obesity syndromes. The published research program for melanotan II, bremelanotide's structural predecessor in the melanocortin peptide lineage, provides additional context for the receptor pharmacology underlying this compound class. Batch-verified PT-141 from SpartaLabs is available for research applications.

References

1. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID: 12851303. DOI: 10.1111/j.1749-6632.2003.tb03168.x

2. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PMID: 14963471. DOI: 10.1038/sj.ijir.3901139

3. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-1071. PMID: 18206919. DOI: 10.1016/j.juro.2007.10.068

4. Halpern JA, Hill R, Brannigan RE. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Ther Adv Drug Saf. 2017;8(4):125-133. PMID: 27977473. PMC: PMC5338879. DOI: 10.1177/2042098616685893

5. Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health Issues. 2017;27(3):365-372. PMC: PMC5384512. DOI: 10.1016/j.whi.2017.01.002

6. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500

7. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599847. DOI: 10.1097/AOG.0000000000003506

8. Browning KD, Bhatt DL, Maher EM, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Sex Med. 2022;19(12):1793-1806. PMID: 36189794. PMC: PMC9525110. DOI: 10.1016/j.jsxm.2022.09.004

9. Clayton AH, Simon JA, Kingsberg SA, Brown L, Morrison MF. Safety Profile of Bremelanotide Across the Clinical Development Program. Clin Drug Investig. 2022;42(4):335-345. PMID: 35147466. DOI: 10.1007/s40261-022-01119-z